Ocugen Inc. (OCGN): What Top Wall Street Players are Saying
Mizuho Securities believes biotech firm Ocugen Inc. (NASDAQ: OCGN) is undervalued. Its business prospects extend beyond the development of a COVID-19 vaccine. According to Mizuho, Ocugen is now being evaluated exclusively on the commercial possibilities of its COVID-19 vaccine, which is already licensed for adult use in Mexico and is being reviewed by Canadian regulators. […]
